BTIG Targeted Therapeutics Conference

BTIG hosted the “BTIG Targeted Therapeutics Conference” on Monday, February 24, 2020 in New York. BTIG Biotechnology Analysts Robert “Bert” Hazlett, Amanda Murphy, CFA and Thomas Shrader, PHD, CFA hosted the conference in addition to BTIG Healthcare Strategy and Franchise Sales Specialists Mikhail Keyserman, CMT, CFTe, and Michael Karmiol. The firm’s private event included one-on-one meetings and panels featuring industry leaders from several embryonic and mature therapeutic companies.
Discussion topics included breast cancer, progress and challenges regarding novel immune effector cells, gene therapy for rare diseases, modulating gene expression with small genetic elements, DMD treatments, targeted small molecule oncologics and neorodegeneration.

For more information about the conference, email [email protected]. Please note that participants must be pre-registered to attend.


This information was prepared for BTIG, LLC institutional clients. The information contained herein has been gathered from multiple sources and is believed to be reliable. However, BTIG, LLC has not independently verified the accuracy of the content and does not make any representations as to the accuracy or completeness of this information. The information is subject to change without notice and BTIG, LLC has no obligation to provide any updates or changes. BTIG, LLC is providing this data for informational purposes and does not believe that it is sufficient to base an investment decision on. This information should not be regarded as a solicitation or recommendation of any particular security or to engage in any trading strategy. BTIG, LLC does and may seek to do business, including investment banking and/or other capital markets business, with companies which are the subject of Corporate Access services.